Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (NYSE: HLN) covers the month of September 2025. The report discloses the Company's total voting rights and capital structure as of August 31, 2025. Haleon operates as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a capital disclosure and does not contain financial performance data.
Material Changes
The filing provides the following capital structure data as of August 31, 2025:
- Total Ordinary Shares Issued: 8,959,221,411 (par value £0.01 each).
- Treasury Shares: 3,880,205.
- Ordinary Shares with Voting Rights: 8,955,341,206.
No material changes to financial performance or operational strategy are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves solely to inform shareholders of the denominator required for calculating notifiable interests under the FCA's Disclosure Guidance and Transparency Rules.
Key Facts for Investor Verification
- Verify the number of voting shares (8,955,341,206) for compliance with disclosure thresholds.
- Confirm the count of treasury shares (3,880,205) held by the Company.
- Note that this filing does not include quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for performance metrics.